[1] 涂平.痤疮治疗新进展--中国痤疮治疗共识会推荐治疗方案.中华皮肤科杂志,2003,36(7):421-422. [2] Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol,2003,49(Suppl):S1-S37. [3] 中国医师协会皮肤科医师分会《中国痤疮治疗指南》专家组. 中国痤疮治疗指南.临床皮肤科杂志,2008,37(5):339-342. [4] Degitz K, Placzek M, Borelli C, et al.Pathophysiology of acne. J Dtsch Dermatol Ges. 2007,5(4):316-323. [5] Thiboutot D,Gollnick H, Bettoli V,et al.New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.;J Am Acad Dermatol.2009,60(5 Suppl):S1-S50. [6] Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol. 2003,49(3 Suppl):S200-S210. [7] Glass D, Boorman GC, Stables GI, et al.A placebo-controlled clinical trial to compare a gel containing a combination of isotretinoin (0.05%) and erythromycin (2%) with gels containing isotretinoin (0.05%) or erythromycin (2%) alone in the topical treatment of acne vulgaris. Dermatology,1999,199(3):242-247. [7] Mills OH Jr, Kligman AM. Treatment of acne vulgaris with topically applied erythromycin and tretinoin. Acta Derm Venereol, 1978,58(6):555-557. [9] Mills OH Jr, Thornsberry C, Cardin CW, et al.Bacterial resistance and therapeutic outcome following three months of topical acne therapy with 2% erythromycin gel versus its vehicle. Acta Derm Venereol, 2002, 82(4):260-265. [10] Eady AE, Cove JH, Layton AM. Is antibiotic resistance in cutaneous propionibacteria clinically relevant? Implications of resistance for acne patients and prescribers. Am J Clin Dermatol,2003,4(12):813-831. [11] Stein RH, Lebwohl M. Acne therapy: clinical pearls. Semin Cutan Med Surg, 2001,20(3):184 –189. [12] Gollnick H, Krautheim A. Topical treatmant in acne: current status and future aspects. Dermatology , 2003,206(1):29–36. |